How long can a person stay on Mounjaro — and what happens when they do?

You've reached your target weight, so does that mean you stop?

This is one of the most common places people find themselves when they ask about duration. The assumption is that Mounjaro works like a course of antibiotics: you finish it and move on. That framing is understandable but does not match how the medicine works or what the evidence shows.

Obesity is a chronic condition shaped by hormones, metabolism and biology that do not simply reset once a target weight is reached. Mounjaro works in part by acting on two gut-hormone pathways, GIP and GLP-1, that regulate appetite and gastric emptying. When treatment stops, those effects stop too. Data from the wider tirzepatide clinical programme show that participants who discontinued after losing weight regained a meaningful portion of it over the following months. That is not a failure of willpower; it reflects the underlying biology.

The question of how long Mounjaro takes to work is separate from how long it can be taken, which depends on individual progress, tolerability and ongoing clinical review. Many people see early appetite changes within weeks; full metabolic effect builds over months. Deciding to stop at the point of early success risks stepping off before the treatment has finished its job. Any decision to reduce or discontinue should come from a conversation with your prescriber, not from hitting a number on the scales.

What the licence and NICE guidance actually say about treatment length

The Mounjaro UK Summary of Product Characteristics, available in full on the electronic Medicines Compendium (eMC), does not set a maximum duration for weight management use. It licenses tirzepatide as an adjunct to a reduced-calorie diet and increased physical activity for adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present.

NICE's appraisal of tirzepatide, TA1026, includes one practical checkpoint: if a patient has not lost at least 5% of their starting body weight after six months at the highest dose they can tolerate, continuing treatment should be reviewed. This is a progress threshold, not a time limit. It exists to avoid patients carrying on with a medicine that is not helping them.

If treatment is working (weight is reducing or being maintained at a level that benefits health, and the person tolerates the medicine well) there is no clinical rule that ends it. The prescriber reassesses regularly, weighing ongoing benefit against any risks or side effects, and that assessment guides everything. Patients transferring from another service or seeking longer-term information on duration for weight loss should bring any previous prescription records so their reviewing prescriber has the full picture.

Evidence from SURMOUNT-1 and what it tells us about sustained use

The core clinical evidence for Mounjaro's weight-management use comes from SURMOUNT-1, a 72-week trial involving 2,539 adults with obesity or overweight and at least one weight-related condition, published in the New England Journal of Medicine. At the 15mg dose, average body-weight reduction reached around 20–21%, and critically, that reduction was sustained across the trial period rather than peaking early and plateauing to nothing.

72 weeks is roughly 17 months. That is the current evidence base, meaning we have good data over that range. Research into longer use is ongoing, and real-world prescribing is accumulating experience beyond trial timelines. What the SURMOUNT-1 data confirms is that continued use during the trial period was associated with continued benefit, not diminishing returns that would argue for an early stop.

The cost of treatment over time is a fair consideration, and you can explore what is included in the consultation and treatment process to understand the full picture before starting. For those weighing up the longer-term picture, further detail on how long you can be on Mounjaro covers additional aspects that come up in clinical conversation.

How an ongoing private prescription actually works at each review stage

At a private pharmacy like ours, there is no automatic repeat. Every time treatment continues, a prescriber reviews it. That is not a formality. It is the clinician checking that your weight trajectory, any side effects and your overall health picture still support the medicine. Our clinical team looks at this evidence before each repeat is authorised.

Side effects, if they occur, are typically gastrointestinal (nausea, some digestive disruption, occasional constipation or loose stools) and most noticeable in the early weeks or after a dose increase. These tend to settle. Severe, persistent stomach pain that spreads to your back is a different matter and needs urgent medical attention, as the MHRA's guidance on GLP-1 medicines makes clear. If you have concerns between reviews, our aftercare team is available seven days a week.

People sometimes ask whether there is a point at which Mounjaro simply stops working. Some patients notice the rate of loss slowing as they approach a lower body weight, and reading about how long people typically stay on Mounjaro can help set realistic expectations before raising the question at a review. Whether to stay at the current dose, titrate, or discuss a different plan is exactly what a prescriber review is for. Treatment is not a contract with a fixed end date; it is an ongoing clinical relationship, reassessed as your health and goals evolve. If you'd like to understand more about how the process works from the start, our frequently asked questions cover the steps from consultation through to delivery.